Checkmab
Checkmab aims to develop monoclonal antibodies against Treg cells in diseased tissues as immunotherapies against autoimmune diseases.
Based based in European Union (EU), Europe, Middle East, and Africa (EMEA), Checkmab works in biotechnology, life science, product research, founded in 2018.
Within the biotechnology, life science, product research space, the company focuses on its core offering rather than a broad product line.
The business is associated with European Union (EU), Europe, Middle East, and Africa (EMEA).
It is recorded at the Private company stage.
Its team size is recorded as c_00001_00010 employees.
| Sector | Biotechnology, Life Science, Product Research |
|---|---|
| Headquarters | European Union (EU), Europe, Middle East, and Africa (EMEA) |
| Founded | 2018 |
| Employees | c_00001_00010 |
| Stage | Private company |
Website: www.checkmab.eu
Browse related
Full contact details are available to registered Pixilab members.
Create a free account
Create a free account